Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?

Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?

Item
http://www.wikidata.org/entity/Q38631012
Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected?Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.Defining and characterizing sustained remission in patients with rheumatoid arthritis.Drug survival rates and reasons for drug discontinuation in psoriasis.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database.Natural Conformational Sampling of Human TNFα Visualized by Double Electron-Electron Resonance.The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease."Drug-Survival"-Raten und Gründe für den Abbruch von Systemtherapien bei Psoriasis.Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
P2860

Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?

Item
http://www.wikidata.org/entity/Q38631012
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immunogenicity of infliximab a ...... erapeutic efficacy and safety?
@en
type
label
Immunogenicity of infliximab a ...... erapeutic efficacy and safety?
@en
prefLabel
Immunogenicity of infliximab a ...... erapeutic efficacy and safety?
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Immunogenicity of infliximab a ...... erapeutic efficacy and safety?
@en
P2093
P2860
P304
P31
P356
10.1517/14740338.2016.1112375
P407
P433
P478
P577
P698
P921